HF
NKTR icon

HRT Financial’s Nektar Therapeutics NKTR Stock Holding History

HRT Financial’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-12,400
Closed -$705K – 3745
2025
Q3 		$705K Buy
+12,400
New +$410K ﹤0.01% 1697

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

HRT Financial's NKTR Position: Q1 2026 in Review

HRT Financial reduced its Nektar Therapeutics (NKTR) stake by 59% in Q1 2026, selling an estimated $5.85M and leaving 70,667 shares worth $5.08M. The position accounts for 0.01% of the portfolio, ranked #986.

HRT Financial first reported a position in NKTR in Q2 2018 and has held it in 20 quarters since. The position peaked at $7.33M in Q4 2025. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • HRT Financial held 70,667 shares of Nektar Therapeutics worth $5.08M as of Q1 2026.
  • HRT Financial sold 102,776 Nektar Therapeutics shares in Q1 2026, an estimated $5.85M.
  • Nektar Therapeutics made up 0.01% of HRT Financial's portfolio in Q1 2026, its #986 holding.
  • HRT Financial first reported a position in Nektar Therapeutics in Q2 2018 and has held it in 20 quarters since.
  • HRT Financial's Nektar Therapeutics position peaked at $7.33M in Q4 2025.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.